Repligen Co. (NASDAQ:RGEN) Receives Consensus …

3 days ago · The company has a market cap of $8.68 billion, a price-to-earnings ratio of -418.53, a PEG ratio of 4.64 and a beta of 0.97. Repligen (NASDAQ:RGEN - Get Free Report) last …

$8.68
OFF

Repligen Co. (NASDAQ:RGEN) Receives Consensus …

2 weeks from now

3 days ago · The company has a market cap of $8.68 billion, a price-to-earnings ratio of -418.53, a PEG ratio of 4.64 and a beta of 0.97. Repligen (NASDAQ:RGEN - Get Free Report) last …

marketbeat.com

90%
OFF

Analysts Set Repligen Co. (NASDAQ:RGEN) Price Target At $185.20

2 weeks from now

12 hours ago · The firm had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. Repligen had a positive return on equity of 3.90% and …

etfdailynews.com

$190.25
OFF

Repligen Co. (NASDAQ:RGEN) Receives $190.25 Consensus Price

2 weeks from now

Oct 11, 2024 · Shares of Repligen Co. (NASDAQ:RGEN – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the ten research firms that are presently …

techdows.com

$0.43
OFF

Repligen Co. (NASDAQ:RGEN) Receives Average Recommendation …

2 weeks from now

Dec 18, 2024 · The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts' consensus estimates of $0.34 by $0.09. Repligen had a positive return on …

marketbeat.com

$185.20
OFF

Repligen Co. (NASDAQ:RGEN) Receives $185.20 Consensus Price …

2 weeks from now

Dec 21, 2024 · The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen has a 52-week low of $113.50 and a 52-week high of $211.13. …

americanbankingnews.com

$230.00
OFF

Repligen Co. (NASDAQ:RGEN) Receives Consensus Rating Of …

2 weeks from now

Jun 1, 2024 · A number of analysts have recently commented on RGEN shares. JPMorgan Chase & Co. reduced their price target on shares of Repligen from $230.00 to $200.00 and set an …

americanbankingnews.com

$199.44
OFF

Repligen Co. (NASDAQ:RGEN) Receives $199.44 Consensus Price …

2 weeks from now

Aug 9, 2023 · Repligen Co. ( NASDAQ:RGEN – Get Free Report) has earned an average rating of “Moderate Buy” from the nine research firms that are presently covering the company, …

americanbankingnews.com

$207.00
OFF

RBC Capital Keeps Their Buy Rating On Repligen (RGEN)

2 weeks from now

1 day ago · RBC Capital analyst Conor McNamara maintained a Buy rating on Repligen (RGEN – Research Report) on January 10 and set a price target of $207.00. The company’s shares …

businessinsider.com

$4
OFF

Four Bergen NJ Towns To Receive Federal Funds For Flooding

2 weeks from now

Mar 12, 2024 · Englewood, Emerson, Leonia and Tenafly will share in $4.7 million in federal funding for flood prevention and mitigation efforts.

northjersey.com

$0.43
OFF

Repligen (RGEN) Stock Price, News & Analysis - MarketBeat

2 weeks from now

2 days ago · Repligen Co. (NASDAQ:RGEN) announced its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the …

marketbeat.com

$185.20
OFF

Repligen (RGEN) Stock Forecast And Price Target 2025

2 weeks from now

6 days ago · RGEN's current price target is $185.20. Learn why top analysts are making this stock forecast for Repligen at MarketBeat.

marketbeat.com

FAQs about Repligen Co. (NASDAQ:RGEN) Receives Consensus … Coupon?

Should you buy Repligen co (RGEN) stock?

Shares of Repligen Co. (NASDAQ:RGEN – Get Free Report) have earned an average recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the company. ...

Should you buy Repligen (Repligen)?

McNamara covers the Healthcare sector, focusing on stocks such as Hologic, Illumina, and QuidelOrtho. According to TipRanks, McNamara has an average return of -11.5% and a 33.55% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Repligen with a $198.17 average price target. ...

Is Repligen a good stock to buy?

Wolfe Research assumed coverage on shares of Repligen in a report on Thursday, November 14th. They set a “peer perform” rating for the company. Finally, Canaccord Genuity Group assumed coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. ...

What is the average 12 month price target for Repligen?

The average 12 month price target among analysts that have issued ratings on the stock in the last year is $185.20. A number of equities analysts have issued reports on the company. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. ...

How much will Repligen (Repligen) earn per share?

On average, sell-side analysts expect that Repligen will post 1.54 earnings per share for the current year. (Get Free Report Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. ...

How much did Repligen (RGEN) earn in a quarter?

Repligen Co. (RGEN) reported earnings of $159.20 million in the last quarter, compared to analysts' expectations of $165.93 million. The biotechnology company announced its earnings data on Wednesday, August 2nd, and reported earnings per share (EPS) of $0.53, which topped analysts' consensus estimates of $0.49 by $0.04. ...